These results are in concordance with the current knowledge that amplified tumors from distinct tumor types respond to targeted therapies directed at the amplification, as occurs with ERBB2/HER2 or MET-amplified tumors [27,28]. This evidence concerns the gene ERBB2 and neoplasm.